Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer

Mack, Philip C.; Gomez, Jorge; Rodilla, Ananda M.; Carreño, Juan Manuel; Hsu, Chih–Yuan; Rolfo, Christian; Meshulami, Noy; Moore, Amy; Brody, Rachel; King, Jennifer C.; Treatman, Jacquelyn D.; Lee, Sooyun; Raskin, Ariel; Srivastava, Komal; Gleason, Charles; Miguel-Perez, Diego de; Tcheou, Johnstone; Bielak, Dominika; Acharya, Rudra Prasad; Gerber, David E.; Rohs, Nicholas; Henschke, Claudia I.; Yankelevitz, David F.; Simon, Viviana; Minna, John D.; Bunn, Paul A.; García‐Sastre, Adolfo; Krammer, Florian; Shyr, Yu; Hirsch, Fred R.; Andre, Dalles; Alshammary, Hala; Bakel, Harm van; Bermudez-Gonzalez, Maria; Cai, Gianna; Cognigni, Christian; Floda, Daniel; Firpo, A.; Kleiner, Giulio; Lyttle, Neko; Mendez, Wanni A.; Mulder, Lubbertus C. F.; Oostenink, Annika; Rooker, Aria; Salimbangon, Ashley Beathrese T.; Saksena, Miti; Sominsky, Levy A.; Sordillo, Emilia Mia

doi:10.1016/j.ccell.2022.04.012

Cited by 15 publications

(24 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our own studies conducted at the same time, we found a 5% subset of 114 patients with NSCLC in whom antibody titers were undetectable (measured at zero) despite full courses of mRNA vaccines, a phenomenon not observed in our controls despite age-matching. 7 Other pan-cancer studies have reported similar results, including the CANVAX study, which evaluated more than 750 patients with cancer, also identifying a subset with substantially diminished antibody levels and neutralization activity. 8 Although the CANVAX study included 193 patients with lung cancer, their publication analyzed all patients with solid tumors as a group and only baseline vaccine responses were reported.…”

mentioning

confidence: 68%

Longitudinal Analyses of COVID-19 Vaccination in Patients With Lung Cancer: Antibody Responses and Variant-Specific Neutralization

Mack

Hirsch

Bunn

et al. 2022

JCO

Self Cite

View full text Add to dashboard Cite

Declared a pandemic in March 2020, the COVID-19 infection disseminated with a swiftness and severity unprecedented in modern times. Doctors and health care workers from multiple specialties, including those in oncology, were called to the frontlines to confront this new disease. For the thoracic oncology community, three fundamental questions immediately arose: how would infection with SARS-CoV-2 affect the treatment and progression of lung cancer; how would a diagnosis of lung cancer interact with and potentially exacerbate COVID-19 infection; and of course, how do we provide appropriate diagnosis, staging, and complex treatment/follow-up regimens during the pandemic? These overarching questions do not do justice to the underlying complexity inherent in the collision of these two diseases. Unknown at the time, and still in question today, are issues concerning cellular biology, immunology, inflammation, treatment planning, comorbidities, and risk management across disparate members of the lung cancer patient community.

show abstract

mentioning

confidence: 68%

Longitudinal Analyses of COVID-19 Vaccination in Patients With Lung Cancer: Antibody Responses and Variant-Specific Neutralization

Mack

Hirsch

Bunn

et al. 2022

JCO

Self Cite

View full text Add to dashboard Cite

show abstract

“…Correlation between anti-S antibody titers and neutralization activity in patients with cancer has been demonstrated [31]. However, the emergence of the Omicron (B.1.1.529) variant which was discovered in November 2021 and then spread quickly globally, the situation changed.…”

Section: Discussionmentioning

confidence: 99%

“…Studies looking at immunogenicity of a 3 rd dose of COVID-19 vaccines have reported that a subset of these patients can be induced to have an immune response with the 3 rd dose of the COVID-19 vaccines. [17,30] Correlation between anti-S antibody titers and neutralization activity in patients with cancer has been demonstrated [31]. However, the emergence of the Omicron (B.1.1.529) variant which was discovered in November 2021 and then spread quickly globally, the situation changed.…”

Section: Discussionmentioning

confidence: 99%

“…However, the emergence of the Omicron (B.1.1.529) variant which was discovered in November 2021 and then spread quickly globally, the situation changed. Omicron, with its extensive mutations in neutralizing epitopes, is able to at least partially evade in vitro neutralizing antibodies induced by 3 rd doses in patients with cancer [31,32]. The potential utility and timing of a 4 th COVID-19 vaccine dose has been brought up especially for those who are at risk for poor seroconversion after 3 rd doses [33], with the Centers for Disease Control (CDC) recommending 2 additional boosters following a 3-vaccine primary series [34].…”

Section: Discussionmentioning

confidence: 99%

“…The potential utility and timing of a 4 th COVID-19 vaccine dose has been brought up especially for those who are at risk for poor seroconversion after 3 rd doses [33], with the Centers for Disease Control (CDC) recommending 2 additional boosters following a 3-vaccine primary series [34]. These variants in part overcome vaccine-induced immunity and are resistant to many of the available monoclonal antibody products [31,32,35].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and longevity of immune response to 3^rd COVID-19 vaccine and effectiveness of a 4^th dose in severely immunocompromised patients with cancer

Thakkar

Pradhan

Duva

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Cancer patients show increased morbidity with COVID-19 and need effective immunization strategies. We demonstrate that a 3rd dose of COVID-19 vaccine leads to seroconversion in 57% of patients that were seronegative after primary vaccination. The immune response is durable as assessed by anti-S antibody titers, T-cell activity and neutralization activity against wild-type SARS-CoV2 and BA1.1.529 at 6 months of follow up. A subset of severely immunocompromised hematologic malignancy patients were unable to mount adequate immune response after the 3rd dose and were treated with a 4th dose in a prospective clinical trial which led to adequate immune-boost in 67% of patients. Low baseline IgM levels and CD19 counts were associated with inadequate seroconversion. Booster doses induced limited neutralization activity against the Omicron variant. These results indicate that vaccine booster-induced immunity is durable in cancer patients and additional doses can further stimulate immunity in a subset of hematologic malignancy patients.Statement of significanceWe demonstrate that a 3rd dose of vaccine leads to seroconversion in 57% of negative patients with durable immune responses at 6 months. A 4th dose of vaccine can seroconvert hematologic malignancy patients with higher baseline IgM and CD19 levels.

show abstract

COVID‐19 and cancer: Dichotomy of the menacing dilemma

Ghosh,

Tabassum,

Basu

2023

MedComm – Oncology

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID‐19) pandemic brought about unprecedented challenges to global healthcare systems. Among the most vulnerable populations are cancer patients, who face dilemmas due to their compromised immune systems and the intricate interplay with the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus. This comprehensive review delves into the multifaceted relationship between COVID‐19 and cancer. Through an analysis of existing literature and clinical data, this review unravels the structural intricacies of the virus and examines its profound implications for cancer patients, thereby bridging the knowledge gap between virology and oncology. The review commences with an introduction regarding the COVID‐19 pandemic and cancer. It then transitions into a detailed examination of the SARS‐CoV‐2 virus and its variants such as Alpha (PANGO lineage B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529 lineage). Subsequently, an insightful analysis of the impact of COVID‐19 on major cancer types (viz., Lung, Colon, Brain, and gastrointestinal cancer) is elaborated. Finally, the therapeutic avenues, oncological care, and management are discussed. The nexus between COVID‐19 and cancer adds a layer of complexity to patient care, emphasizing the importance of tailored approaches for those grappling with both conditions. Amid the landscape defined by the evolving viral strains, this review navigates through the multifaceted implications of COVID‐19 on cancer patients and underscores the significance of integrating virology and oncology.

show abstract

Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer

Cited by 15 publications

References 10 publications

Longitudinal Analyses of COVID-19 Vaccination in Patients With Lung Cancer: Antibody Responses and Variant-Specific Neutralization

Longitudinal Analyses of COVID-19 Vaccination in Patients With Lung Cancer: Antibody Responses and Variant-Specific Neutralization

Efficacy and longevity of immune response to 3^rd COVID-19 vaccine and effectiveness of a 4^th dose in severely immunocompromised patients with cancer

COVID‐19 and cancer: Dichotomy of the menacing dilemma

Contact Info

Product

Resources

About

Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer

Cited by 15 publications

References 10 publications

Longitudinal Analyses of COVID-19 Vaccination in Patients With Lung Cancer: Antibody Responses and Variant-Specific Neutralization

Longitudinal Analyses of COVID-19 Vaccination in Patients With Lung Cancer: Antibody Responses and Variant-Specific Neutralization

Efficacy and longevity of immune response to 3rd COVID-19 vaccine and effectiveness of a 4th dose in severely immunocompromised patients with cancer

COVID‐19 and cancer: Dichotomy of the menacing dilemma

Contact Info

Product

Resources

About

Efficacy and longevity of immune response to 3^rd COVID-19 vaccine and effectiveness of a 4^th dose in severely immunocompromised patients with cancer